Warning Letter Record: Leading Edge Health Inc. (June 17, 2026) — Unapproved New Drugs/Misbranded

FDA Warning Letter — Violations FDA cited at Leading Edge Health Inc.

WARNING LETTER Leading Edge Health Inc. MARCS-CMS 729193 — June 17, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Leading Edge Health Inc. 300-1095 McKenzie Avenue Victoria BC V8P 2L5 Canada support@leadingedgehealth.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States June 17, 2026 Leading Edge Ltd. 171 Arch. Makariou III Ave Vanezis Business Center, Office 401 3027 Limassol, Cyprus LEM Processing LLC 6130 Elton Ave Las Vegas, NV 89107 WARNING LETTER Reference Number: 729193 To Leading Edge Health/LEM Processing: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. FDA Review Violations were identified and documented during a review of your website https://www.leadingedgehealth.com/ in May 2026. Based on our review, “Erectin Stimulating Gel” and “VigRX Delay Wipes” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website, “Erectin Stimulating Gel” and “VigRX Delay Wipes” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following: Erectin Stimulating Gel On the webpage https://www.leadingedgehealth.com/products/erectin-stimulating-gel/: “Erectin Stimulating Gel is nicknamed the INSTANT ERECTION formula.” “Rock Hard Erections.” “Longer-Lasting Erections.” VigRX Delay Wipes On the webpage https://www.leadingedgehealth.com/products/vigrx-delay-wipes/: “Zanthoxylum Oil has been used for centuries as an anti-fungal treatment and for its healing properties. It has a numbing effect that makes it perfect for guys who ejaculate too early.” “Peony Extract helps blood circulation and soothes nerves.” “Erectin Stimulating Gel” and “VigRX Delay Wipes” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are